综述

他汀类药物在慢性阻塞性肺疾病治疗中的研究进展

展开
  • 上海瑞金医院集团闵行中心医院急诊科, 上海 201100
周 健(1976—), 男, 住院医师, 学士;电子信箱: zj021976@163.com。

网络出版日期: 2010-12-31

Research progress of role of statins in treatment of chronic obstractive pulmonary disease

Expand
  • Department of Emergency, Minhang Central Hospital, Shanghai Ruijin Hospital Group, Shanghai 201100, China

Online published: 2010-12-31

摘要

慢性阻塞性肺疾病(COPD)是一种具有气流受限特征的可以预防和治疗的疾病。气流受限不完全可逆,呈进行性发展,与肺部对有害气体或颗粒的异常炎症反应有关。他汀类药物是3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂,是最为经典和有效的降脂药物,广泛应用于心血管疾病的治疗。近年来研究发现,他汀类药物通过抗金属蛋白酶、抗氧化、抗炎症介质及细胞因子、抑制黏附分子表达、降低C反应蛋白等环节起到抗炎作用,缓解了COPD患者的肺功能,降低了发病率和病死率。

本文引用格式

周 健, 凌美蓉, 邓星奇 . 他汀类药物在慢性阻塞性肺疾病治疗中的研究进展[J]. 上海交通大学学报(医学版), 2010 , 30(12) : 1569 . DOI: 10.3969/j.issn.1674-8115.2010.12.028

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by progressive and minimally reversible airflow limitation with systemic inflammation, which can be prevented and treated. Statins reduce cholesterol levels by inhibiting 3-hydroxy-3-methlglutaryl coenzyme A(HMG-CoA) reductase, and have an established role in the treatment of cardiovascular diseases. Recent studies have revealed that statins have profound anti-inflammatory effects by reducing induction of matrix metalloproteinase, expression of cytokines and cell adhesion molecules, antioxidant state and C-reactive protein, which decreases lung function deterioration, morbidity and mortality in COPD.

文章导航

/